




RealRate

PHARMACEUTICAL 2022

Sonnet Biotherapeutics Holdings Inc
Rank 280 of 471



RealRate

The First AI Rating Agency

www.realrate.ai



PHARMACEUTICAL 2022

Sonnet Biotherapeutics Holdings Inc Rank 280 of 471



The relative strengths and weaknesses of Sonnet Biotherapeutics Holdings Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Sonnet Biotherapeutics Holdings Inc compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 34% points. The greatest weakness of Sonnet Biotherapeutics Holdings Inc is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 50% points.

The company's Economic Capital Ratio, given in the ranking table, is 255%, being 21% points below the market average of 275%.

Input Variable	Value in 1000 USD
Assets, Current	28,812
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	6,703
Liabilities, Non-Current	31
Other Assets	123
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	-22
Other Revenues	609
Property and Equipment	59
Research and Development	16,635
Selling, General and Administrative Expense	8,937

Output Variable	Value in 1000 USD
Assets	28,994
Liabilities	6,734
Expenses	25,571
Revenues	609
Stockholders Equity	22,260
Net Income	-24,984
Comprehensive Net Income	-24,984
BaseVar	30,965
ECR before LimitedLiability	132%
Economic Capital Ratio	255%